Marita Stevens

1.4k total citations
38 papers, 985 citations indexed

About

Marita Stevens is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Marita Stevens has authored 38 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 18 papers in Epidemiology and 12 papers in Virology. Recurrent topics in Marita Stevens's work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (12 papers) and Respiratory viral infections research (11 papers). Marita Stevens is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (12 papers) and Respiratory viral infections research (11 papers). Marita Stevens collaborates with scholars based in Belgium, United States and United Kingdom. Marita Stevens's co-authors include René Kerstens, Herta Crauwels, Simon Vanveggel, Katia Boven, Annemie Buelens, Georges Coremans, Martine De Pauw, William Spreen, Richard M. W. Hoetelmans and Peter Williams and has published in prestigious journals such as Blood, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Marita Stevens

38 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marita Stevens Belgium	18	659	451	237	158	143	38	985
Marisela Silva United States	6	537 0.8×	77 0.2×	213 0.9×	170 1.1×	147 1.0×	11	708
Rakhi Kohli United States	10	347 0.5×	65 0.1×	256 1.1×	14 0.1×	103 0.7×	19	602
Maame Efua Sampah United States	10	160 0.2×	134 0.3×	88 0.4×	27 0.2×	13 0.1×	19	497
Shweta Sharma United States	14	395 0.6×	245 0.5×	135 0.6×	6 0.0×	225 1.6×	48	610
Hector Bolívar United States	13	223 0.3×	140 0.3×	110 0.5×	16 0.1×	306 2.1×	34	542
Claudia Pinacchio Italy	16	275 0.4×	96 0.2×	96 0.4×	12 0.1×	40 0.3×	29	656
P. D’Argenio Italy	9	280 0.4×	155 0.3×	133 0.6×	5 0.0×	96 0.7×	13	498
Pierre de Truchis France	13	259 0.4×	148 0.3×	181 0.8×	3 0.0×	30 0.2×	50	644
Sergio Reus Spain	14	253 0.4×	124 0.3×	291 1.2×	3 0.0×	128 0.9×	64	633
Kimberly Bergman United States	9	85 0.1×	88 0.2×	117 0.5×	38 0.2×	6 0.0×	17	361

Countries citing papers authored by Marita Stevens

Since Specialization

Citations

This map shows the geographic impact of Marita Stevens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marita Stevens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marita Stevens more than expected).

Fields of papers citing papers by Marita Stevens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marita Stevens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marita Stevens. The network helps show where Marita Stevens may publish in the future.

Co-authorship network of co-authors of Marita Stevens

This figure shows the co-authorship network connecting the top 25 collaborators of Marita Stevens. A scholar is included among the top collaborators of Marita Stevens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marita Stevens. Marita Stevens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferrero, Fernando, Chien‐Yu Lin, Johannes G. Liese, et al.. (2024). CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Pediatric Drugs. 26(4). 411–427. 6 indexed citations

Falsey, Ann R., Edward E. Walsh, Stacey L. House, et al.. (2024). Assessment of Illness Severity in Adults Hospitalized With Acute Respiratory Tract Infection due to Influenza, Respiratory Syncytial Virus, or Human Metapneumovirus. Influenza and Other Respiratory Viruses. 18(5). e13275–e13275. 10 indexed citations

Nilsson, Anna, John Pullman, Piotr Napora, et al.. (2023). A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection. Clinical Microbiology and Infection. 29(10). 1320–1327. 9 indexed citations

Loge, Christine de la, et al.. (2021). Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation. Patient Related Outcome Measures. Volume 12. 247–265. 3 indexed citations

Huntjens, Dymphy, et al.. (2017). Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects. Clinical Pharmacokinetics. 56(11). 1331–1342. 11 indexed citations

Lombaard, Johan, Torsak Bunupuradah, Patricia M. Flynn, et al.. (2016). Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents. The Pediatric Infectious Disease Journal. 35(11). 1215–1221. 7 indexed citations

Margolis, David A., Cynthia Brinson, Graham Smith, et al.. (2015). Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases. 15(10). 1145–1155. 157 indexed citations

Behrens, Georg M. N., Bart Rijnders, Mark Nelson, et al.. (2014). Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care and STDs. 28(4). 168–175. 23 indexed citations

Spreen, William, Peter Williams, David M. Margolis, et al.. (2014). Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(5). 487–492. 96 indexed citations

10.

Crauwels, Herta, Rolf P. G. van Heeswijk, Marita Stevens, et al.. (2013). Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.. PubMed. 15(2). 87–101. 48 indexed citations

11.

Antinori, Andrea, Bonaventura Clotet, Jan Fourie, et al.. (2013). Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks. HIV Medicine. 14(7). 391–400. 33 indexed citations

12.

Molina, Jean‐Michel, et al.. (2013). Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less. AIDS. 27(6). 889–897. 22 indexed citations

13.

Rimsky, L, Veerle Van Eygen, Annemie Hoogstoel, et al.. (2013). 96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials. Antiviral Therapy. 18(8). 967–977. 35 indexed citations

14.

Crauwels, Herta, et al.. (2012). Absence of a pharmacokinetic interaction of rilpivirine with the P‐glycoprotein substrate digoxin in healthy volunteers. Journal of the International AIDS Society. 15(S4). 1–2. 2 indexed citations

15.

Nelson, Mark, Nathan Clumeck, Pablo Tebas, et al.. (2012). Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. Journal of Antimicrobial Chemotherapy. 67(8). 2020–2028. 30 indexed citations

16.

Mills, Anthony, Andrea Antinori, Bonaventura Clotet, et al.. (2011). Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks. 1 indexed citations

17.

Stevens, Marita & M. J. C. Asher. (2005). Preliminary investigations into the interactions between Beet mild yellowing virus (BMYV) and Beet necrotic yellow vein virus (BNYVV) in susceptible and rhizomania-resistant varieties. Rothamsted Repository (Rothamsted Repository). 3 indexed citations

18.

Coremans, Georges, René Kerstens, Martine De Pauw, & Marita Stevens. (2003). Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate Relief. Digestion. 67(1-2). 82–89. 93 indexed citations

19.

Sloots, Cornelius E. J., Alexander C. Poen, René Kerstens, et al.. (2002). Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Alimentary Pharmacology & Therapeutics. 16(4). 759–767. 73 indexed citations

20.

Boddy, Alan V., CR Pinkerton, Ian Lewis, et al.. (1998). Validation of pharmacologically-guided dosing of carboplatin in paediatric patients. British Journal of Cancer. 78. 9–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact